Breaks Categories: News

WednesdayMay 22, 2024 2:44 pm

BioMedNewsBreaks — SOHM, Inc. (SHMN) Continues to Advance Groundbreaking Technology

SOHM (OTC: SHMN), a leading generic pharmaceutical and upstart biotechnology company, today announced its ongoing work on ABBIE (A Binding Based Integrase Enzyme), a revolutionary retroviral integrase with a linked dCas9 DNA binding domain. The technology holds the potential to revolutionize genome editing by allowing for precise and targeted integration of predesigned donor DNA into the genome of cells. The revolutionary new ABBIE system, due to SOHM’s committed, consistent and focused approach by lead scientists at its lab at UACI in Tucson, Arizona, is due to be sold as off-the-shelf kits in the third quarter of this year. “We are…

Continue Reading

TuesdayMay 21, 2024 1:27 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Schedules Live Investor Webinar, Q&A Session

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceuticals and technology, will be spotlighted in an upcoming webinar, hosted by RedChip Companies. The event is slated for May 30, 2024, and will begin at 4:15 p.m. ET. Nutriband chair Serguei Melnik and CEO Gareth Sheridan will present during the event, which will provide key information for investors regarding current operations and upcoming milestones. To register for the event, visit https://ibn.fm/9REfQ To view the full press release, visit https://ibn.fm/mH9jC About Nutriband Inc. Nutriband is primarily engaged in the development of a portfolio of transdermal pharmaceutical products. The company’s lead product under development…

Continue Reading

MondayMay 20, 2024 2:09 pm

BioMedNewsBreaks – HeartBeam Inc. (NASDAQ: BEAT) Announces Positive Study Data for Its AI Program

HeartBeam (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, today announced the results of a new study demonstrating that HeartBeam AI combined with vectorcardiography (“VCG”) outperformed an expert panel of heart rhythm cardiologists in detecting atrial flutter. Key findings from the analysis show that HeartBeam AI combined with VCG outperformed an expert panel reviewing single-lead ECGs and demonstrated a statistically significant 6% improvement in the detection of atrial flutter cases compared to an expert panel reviewing 12-lead ECGs. “The modern vectorcardiogram is nearly 100 years old, and yet we are cautiously…

Continue Reading

MondayMay 20, 2024 1:17 pm

BioMedNewsBreaks — CNS Pharmaceuticals Inc. (NASDAQ: CNSP) CEO to Present at 2024 Healthcare Company Showcase

CNS Pharmaceuticals (NASDAQ: CNSP) is a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system. The company today announced that its Chief Executive Officer John Climaco will participate in a fireside chat at the Healthcare Company Showcase hosted by Alliance Global Partners. Climaco’s presentation is slated to begin at 1:40 p.m. ET on May 21, 2024. A live webcast will be available on the Events page of CNSP’s website. To view the full press release, visit https://ibn.fm/TQeLP About CNS Pharmaceuticals Inc. CNS Pharmaceuticals is a clinical-stage pharmaceutical company…

Continue Reading

MondayMay 20, 2024 11:47 am

BioMedNewsBreaks — NextPlat Corp’s (NASDAQ: NXPL) GTC Begins Sales of SpaceX’s Starlink as Authorized Reseller

NextPlat (NASDAQ: NXPL, NXPLW), a global e-commerce provider, today announced that its subsidiary, Global Telesat Communications Ltd (“GTC”), through a new joint venture agreement with Pivotel Solutions Inc. (dba “Pulsar”) is now a global authorized reseller of SpaceX’s Starlink satellite-based connectivity products. Under the agreement as as an approved reseller, GTC will immediately begin offering Starlink connectivity services in the U.K. and other international markets serving mobile and maritime-based customers. Pulsar will provide GTC back-end systems support services on behalf of its new Starlink customers. “We are pleased to collaborate with Pulsar to begin offering SpaceX’s revolutionary Starlink, LEO-satellite based…

Continue Reading

ThursdayMay 16, 2024 1:56 pm

BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Releases Q1 2024 Financial, Business Report

CNS Pharmaceuticals (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers in the brain and central nervous system, is reporting its financial and business results for the first quarter 2024, the period ended March 31, 2024. A highlight of the report was that enrollment is nearly completed in a potentially pivotal GBM study evaluating Berubicin with topline data expected in the first half of 2025. In addition, financial results showed a net loss for the quarter of approximately $3.5 million, down from an estimated $4.9 million net loss for the comparable period…

Continue Reading

ThursdayMay 16, 2024 1:33 pm

BioMedNewsBreaks — HealthLynked Corp. (HLYK) Releases Q1 2024 Financial Results

HealthLynked (OTCQB: HLYK), a trailblazer in healthcare technology, today announced its financial results for the first quarter ended March 31, 2024. During the quarter, the company’s revenue reached $1.0 million, an 8% increase compared to the fourth quarter of 2023, underscoring HealthLynked’s resilience and adaptability in managing transitions while maintaining operational efficiency. The announcement noted HealthLynked’s continued strategic focus on cost control, which saw the company reduce operating expenses in the Health Services Division by 33%, SG&A expenses by 9%, and overall operating expenses by 22% in Q1 2024 compared to Q1 2023. The company reported a net loss from…

Continue Reading

ThursdayMay 16, 2024 1:18 pm

BioMedNewsBreaks – Nutriband Inc. (NASDAQ: NTRB) Names Seasoned Business Leader to Board of Directors

Nutriband (NASDAQ: NTRB), a developer of transdermal pharmaceutical solutions, has announced a new member of its board of directors. According to the announcement, Sergei Glinka, a seasoned and highly respected business executive, will serve on the board. An Estonian citizen, Glinka has served in several executive and board roles positions in large European companies, including Automecanica Skb Property Srl., GST Investments OU and TG Biochemicals Ltd. Glinka’s expertise will support and facilitate new licensing and networking opportunities for Nutriband throughout Europe as the company works to expand its AVERSA(TM) technology, which is patented in 45 countries. The announcement noted that…

Continue Reading

ThursdayMay 16, 2024 1:02 pm

BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Releases FY 2023 Financial Results, Provides Business Update

Scinai Immunotherapeutics (NASDAQ: SCNI), a biopharmaceutical company focused on the development of inflammation and immunology (“I&I”) biological products and on providing contract development and manufacturing organization (“CDMO”) services through its Scinai Bioservices business unit, is reporting its full-year financial results for 2023 along with a company update. Highlights of the report included news that, in the first four months of 2024, the company has received CDMO work orders valued at approximately $500,000, with current guidance for this year of approximately $1.25 million in expected revenues. The report also noted that the company is “aggressively advancing” its NanoAb preclinical development, with promising results obtained in a…

Continue Reading

WednesdayMay 15, 2024 1:54 pm

BioMedNewsBreaks — Sigyn Therapeutics Inc. (SIGY) Announces Q1 2024 Financial Results

Sigyn Therapeutics (OTCQB: SIGY), a development-stage medical technology company, today announced financial results for the first quarter ended March 31, 2024. During the quarter, the company reported a loss from operations of $629,972, as compared to an operating loss of $521,258 for the comparable period in 2023. Sigyn Therapeutics’ net loss for Q1 2024 was $758,088 or $0.62 per share, as compared to a net loss of $1,341,036, or $1.39 per share, during Q1 2023. During the first quarter, SIGY completed a 1-for-40 reverse split of its common stock. As a result, 1,224,827 shares of company’s common stock are currently…

Continue Reading